Global Generics & Biosimilars Industry Sets Out Vision To 2030
The IGBA Has Identified Seven Key Actions Necessary For Industry
Headwinds as well as opportunities for the off-patent industry are discussed in a comprehensive new whitepaper by the International Generic and Biosimilar Medicines Association
You may also be interested in...
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.
Lannett has added another respiratory generic to its development partnership with China’s Respirent, in the form of a rival to Boehringer Ingelheim’s tiotropium-based Spiriva Handihaler.
Lupin has broadened its reach in Australia after agreeing a deal to buy local generics developer and distributor Southern Cross.